Literature DB >> 11918234

Total pelvic exenteration: results from a multispecialty team approach to complex cancer surgery.

Y H Ho1, C Cheng, S K Tay.   

Abstract

Total pelvic exenteration is often the only curative option for recurrent or locally advanced pelvic cancers, but it carries a high risk of mortality and morbidity. A dedicated multispecialty team operative approach may provide the expertise to perform this uncommon procedure with favorable outcomes. Data were analyzed from a prospectively collected computerized database. There were 14 patients (2 men; mean age, 54.6 +/- 3.6 years) with mainly cervical cancers, of which 71.4% were recurrent. Anesthetic time was 5 +/- 0.9 hours, intraoperative blood loss was 2.1 +/- 0.5 liters, and postoperative hospitalization was 22 +/- 9.9 days. An ileal conduit was performed in all patients, but intestinal continuity was restorable with colonic J-pouch in 71.4% of the patients. There was no mortality at 30 days or during hospitalization. Complication rates were 35.7%, accounting for reoperations in 28.6%. Recurrences were detected in 50% patients at a mean follow-up of 53.1 +/- 9.2 months. The mean time for cancer recurrence was 13.3 +/- 3.3 months. Fifty percent of those patients had otherwise survived to date. We conclude that a dedicated multispecialty team may perform total pelvic exenteration with minimum mortality and acceptable morbidity.

Entities:  

Mesh:

Year:  2001        PMID: 11918234

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  2 in total

1.  Total cystectomies in the surgical treatment of rectal cancer with prior chemoradiation: analysis of postoperative morbidity and survival.

Authors:  Janusz Oledzki; Maciej Chwaliński; Wojciech Rogowski; Rafał Sopyło; Marek P Nowacki
Journal:  Int J Colorectal Dis       Date:  2003-10-14       Impact factor: 2.571

2.  Selection criteria for the radical treatment of locally advanced rectal cancer.

Authors:  Mansel Leigh Davies; Dean Harris; Mark Davies; Malcolm Lucas; Peter Drew; John Beynon
Journal:  Int J Surg Oncol       Date:  2011-10-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.